Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Pittaluga Website

Stefania Pittaluga, M.D., Ph.D.

Selected Publications

1)  McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, Kwatemaa N, Starling J, Fleisher TA, Long Priel DA, Merideth MA, Giuntoli RL, Evbuomwan MO, Littel P, Marquesen MM, Hilligoss D, Decastro R, Grimes GJ, Hwang ST, Pittaluga S, Calvo KR, Stratton P, Cowen EW, Kuhns DB, Malech HL, Murphy PM.
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
Blood. [Epub ahead of print], 2014.
2)  Menon MP, Evbuomwan MO, Rosai J, Jaffe ES, Pittaluga S.
A subset of Rosai-Dorfman disease cases show increased IgG4-positive plasma cells: another red herring or a true association with IgG4-related disease?.
Histopathology. 64: 455-9, 2014.
3)  Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M, Stoddard J, Ouyang W, Frucht DM, Rao VK, Atkinson TP, Agharahimi A, Hussey AA, Folio LR, Olivier KN, Fleisher TA, Pittaluga S, Holland SM, Cohen JI, Oliveira JB, Tangye SG, Schwartzberg PL, Lenardo MJ, Uzel G.
Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110d result in T cell senescence and human immunodeficiency.
Nat. Immunol. 15: 88-97, 2014.
4)  Huppmann AR, Nicolae A, Slack GW, Pittaluga S, Davies-Hill T, Ferry JA, Harris NL, Jaffe ES, Hasserjian RP.
EBV May Be Expressed in the LP Cells of Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults.
Am. J. Surg. Pathol. 38: 316-24, 2014.
5)  Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, Perkins K, Hornung RL, Folio L, Rosenberg PS, Puck JM, Hsu AP, Lo B, Pittaluga S, Jaffe ES, Fleisher TA, Rao VK, Lenardo MJ.
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.
Blood. 2014.
6)  Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM.
Oncogenic mechanisms in burkitt lymphoma.
Cold Spring Harb Perspect Med. 4, 2014.
7)  O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T.
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
J. Clin. Endocrinol. Metab. jc20132298, 2014.
Click Here to View Expanded Bibliography.

This page was last updated on 2/25/2014.